The South Dakota governor this week signed legislation to expand on a previous 2019 state law that prohibits certain 340B-specific [...] …
Category: PBMs and Payers
Idaho state lawmakers this week introduced a bill to bar drugmaker 340B contract pharmacy restrictions and certain 340B-specific pharmacy benefit [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The New Hampshire state senate will vote next month on a bill to bar certain 340B-specific pharmacy benefit manager (PBM) [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Following the recent passage in the state house, the South Dakota Senate approved a bill earlier this week to bar [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The majority leader of the Utah state senate and a key committee in the Kansas state senate each introduced bills [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The Federal Trade Commission (FTC) and the Department of Health and Human Services (HHS) are requesting comments on how group [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Baptist Health of Alabama sued Humana in federal court over the lack of repayment by the company’s Medicare Advantage (MA) [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Missouri state senators in recent weeks have introduced three bills with provisions to bar pharmacy benefit managers (PBMs) from what 340B providers describe as underpayments and other discriminatory practices.
On Jan. 3, Missouri state Sens. Curtis Trent (R) and Doug
…
Eight Mississippi state senators have introduced a bill to bar drugmakers from restricting 340B contract pharmacy use and pharmacy benefit [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A key healthcare committee in the Iowa House of Representatives recently introduced a bill that would bar drug manufacturer restrictions [...] …